相似文献
1
Can ovarian suppression with gonadotropin-releasing hormone analogs (GnRHa) preserve fertility in cancer patients?
Ann Oncol. 2016 Feb;27(2):357. doi: 10.1093/annonc/mdv554. Epub 2015 Nov 25.
2
Gonadotropin-releasing hormone agonists for ovarian protection during cancer chemotherapy: systematic review and meta-analysis.
Ultrasound Obstet Gynecol. 2018 Jan;51(1):77-86. doi: 10.1002/uog.18934. Epub 2017 Dec 1.
3
Utility of gonadotropin-releasing hormone agonists for fertility preservation in women receiving chemotherapy: pros and cons.
Fertil Steril. 2020 Oct;114(4):725-738. doi: 10.1016/j.fertnstert.2020.08.011.
4
Preservation of gonadal function in women undergoing chemotherapy: a review of the potential role for gonadotropin-releasing hormone agonists.
Am J Obstet Gynecol. 2016 Oct;215(4):415-22. doi: 10.1016/j.ajog.2016.06.053. Epub 2016 Jul 13.
5
Protecting Ovaries During Chemotherapy Through Gonad Suppression: A Systematic Review and Meta-analysis.
Obstet Gynecol. 2015 Jul;126(1):187-95. doi: 10.1097/AOG.0000000000000905.
6
Gonadotropin-Releasing Hormone Agonist Cotreatment During Chemotherapy May Increase Pregnancy Rate in Survivors.
Oncologist. 2015 Nov;20(11):1283-9. doi: 10.1634/theoncologist.2015-0223. Epub 2015 Oct 13.
7
Gonadotropin-Releasing Hormone Agonists During Chemotherapy for Preservation of Ovarian Function and Fertility in Premenopausal Patients With Early Breast Cancer: A Systematic Review and Meta-Analysis of Individual Patient-Level Data.
J Clin Oncol. 2018 Jul 1;36(19):1981-1990. doi: 10.1200/JCO.2018.78.0858. Epub 2018 May 2.
8
Temporary ovarian suppression during chemotherapy to preserve ovarian function and fertility in breast cancer patients: A GRADE approach for evidence evaluation and recommendations by the Italian Association of Medical Oncology.
Eur J Cancer. 2017 Jan;71:25-33. doi: 10.1016/j.ejca.2016.10.034. Epub 2016 Dec 9.
9
Utility of gonadotropin-releasing hormone agonists for fertility preservation in young breast cancer patients: the benefit remains uncertain.
Ann Oncol. 2013 Sep;24(9):2224-35. doi: 10.1093/annonc/mdt196. Epub 2013 May 24.
10
Feasibility and efficacy of gonadotropin-releasing hormone agonists for the prevention of chemotherapy-induced ovarian insufficiency in patients with malignant ovarian germ cell tumours (KGOG 3048R).
Eur J Cancer. 2020 Jul;133:56-65. doi: 10.1016/j.ejca.2020.03.030. Epub 2020 May 19.
引用本文的文献
1
Disparities in access to fertility preservation among adolescents undergoing gonadotoxic therapies.
J Assist Reprod Genet. 2024 Dec;41(12):3559-3565. doi: 10.1007/s10815-024-03253-z. Epub 2024 Sep 26.
2
Gonadotropin Releasing Hormone agonist (GnRHa) during chemotherapy and post-cancer childbirths - a Nationwide population-based cohort study of 24,922 women diagnosed with cancer in Sweden.
EClinicalMedicine. 2023 Dec 7;67:102335. doi: 10.1016/j.eclinm.2023.102335. eCollection 2024 Jan.
3
ProFertil study protocol for the investigation of gonadotropin-releasing hormone agonists (GnRHa) during chemotherapy aiming at fertility protection of young women and teenagers with cancer in Sweden-a phase III randomised double-blinded placebo-controlled study.
BMJ Open. 2023 Dec 9;13(12):e078023. doi: 10.1136/bmjopen-2023-078023.
4
Hot Topics on Fertility Preservation for Women and Girls-Current Research, Knowledge Gaps, and Future Possibilities.
J Clin Med. 2021 Apr 13;10(8):1650. doi: 10.3390/jcm10081650.
5
Burning Questions in the Oncofertility Counseling of Young Breast Cancer Patients.
Breast Cancer (Auckl). 2020 Sep 4;14:1178223420954179. doi: 10.1177/1178223420954179. eCollection 2020.
6
Development and internal validation of a Nomogram for preoperative prediction of surgical treatment effect on cesarean section diverticulum.
BMC Womens Health. 2019 Nov 11;19(1):136. doi: 10.1186/s12905-019-0817-z.
7
Fertility Preservation Using GnRH Agonists: Rationale, Possible Mechanisms, and Explanation of Controversy.
Clin Med Insights Reprod Health. 2019 Aug 21;13:1179558119870163. doi: 10.1177/1179558119870163. eCollection 2019.
8
Fertility preservation in ovarian tumours.
Ecancermedicalscience. 2018 Dec 6;12:885. doi: 10.3332/ecancer.2018.885. eCollection 2018.
本文引用的文献
1
Failure of Ovarian Suppression With Gonadotropin-Releasing Hormone Analogs to Preserve Fertility: An Assessment Based on the Quality of Evidence.
JAMA Oncol. 2016 Jan;2(1):74-5. doi: 10.1001/jamaoncol.2015.3252.
2
Ovarian suppression using luteinizing hormone-releasing hormone agonists during chemotherapy to preserve ovarian function and fertility of breast cancer patients: a meta-analysis of randomized studies.
Ann Oncol. 2015 Dec;26(12):2408-19. doi: 10.1093/annonc/mdv374. Epub 2015 Sep 7.
3
Protecting Ovaries During Chemotherapy Through Gonad Suppression: A Systematic Review and Meta-analysis.
Obstet Gynecol. 2015 Jul;126(1):187-95. doi: 10.1097/AOG.0000000000000905.
4
Adjuvant exemestane with ovarian suppression in premenopausal breast cancer.
N Engl J Med. 2014 Jul 10;371(2):107-18. doi: 10.1056/NEJMoa1404037. Epub 2014 Jun 1.
5
Gonadotropin-releasing hormone agonist for the prevention of chemotherapy-induced ovarian failure in patients with lymphoma: 1-year follow-up of a prospective randomized trial.
J Clin Oncol. 2013 Mar 1;31(7):903-9. doi: 10.1200/JCO.2012.42.8185. Epub 2012 Nov 5.
Zotero 插件